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Prostaglandins, pleiotropic immune modulators that induce protein kinase A (PKA), inhibit gamma inter-
feron induction of class II major histocompatibility complex (MHC) genes. We show that phosphorylation of
CIITA by PKA accounts for this inhibition. Treatment with prostaglandin E or 8-bromo-cyclic AMP or
transfection with PKA inhibits the activity of CIITA in both mouse and human monocytic cell lines. This
inhibition is independent of other transcription factors for the class II MHC promoter. These same treatments
also greatly reduced the induction of class II MHC mRNA by CIITA. PKA phosphorylation sites were identified
using site-directed mutagenesis and phosphoamino acid analysis. Phosphorylation at CIITA serines 834 and
1050 accounts for the inhibitory effects of PKA on CIITA-driven class II MHC transcription. This is the first
demonstration that the posttranslational modification of CIITA mediates inhibition of class II MHC tran-
scription.
Class II molecules of the major histocompatibility complex
(MHC) play a critical role in T-cell-dependent immunity and
the inflammatory response by presenting processed, exogenous
antigens to T helper (Th) cells (reviewed in references 13, 42,
and 50). These important molecules are commonly used as
targets for immune therapies aimed at blocking graft rejection
or promoting the recognition of cancer. Although expressed
constitutively on “professional” antigen-presenting cells
(monocytes/macrophages, B cells, and dendritic cells) class II
MHC can be induced in most cell types and tissues in the
presence of gamma interferon (IFN-g) (1, 3, 9–11, 24, 28, 31,
38, 45, 57, 60, 62). Patients lacking class II MHC have reduced
numbers of CD41 Th cells and succumb to repeated bacterial,
viral, and protozoal infections, generally dying in early child-
hood (39). Class II MHC has been implicated as a contributing
factor for numerous diseases including diabetes, rheumatoid
arthritis, Alzheimer’s disease, and multiple sclerosis (7, 39, 49).
The constitutive and inducible expression of nearly all class
II MHC and related genes is regulated globally at the level of
transcription by the class II transactivator (CIITA) (8, 27, 60).
Transient transfection of CIITA into cells which are class II
MHC deficient or have low-level expression of class II MHC is
sufficient to drive class II MHC transcription and expression
(12, 46, 48). In normal tissues, CIITA expression patterns are
controlled by as many as four promoters, which allow both
constitutive and IFN-g-inducible expression of CIITA (44, 52).
Though not a DNA-binding protein, CIITA is required for the
opening and subsequent activation of class II MHC promoters
through interactions with the ubiquitously expressed transcrip-
tion factors RFX and NF-Y, which recognize the X and Y
DNA elements of class II and class I MHC promoters (41, 54,
64). CIITA contains an N-terminal acidic domain (residues 1
to 125) which can act as a transcription activation domain when
fused to GAL4 DNA-binding sequences (34, 54, 63). A variety
of proteins interact with the acidic domain of CIITA, including
TFIIB, TAFIIs, CREB-binding protein (CBP), and p300 (22,
23, 34, 40, 58), demonstrating that this domain is coupled to
the basal transcription machinery. CIITA also contains a func-
tional GTP-binding domain (26) and a series of C-terminal
leucine-rich repeats that are important for nuclear transloca-
tion (25). Regulation of CIITA-mediated class II MHC tran-
scription results from specific modulation of the CIITA pro-
moter and/or by modification of the transactivation capacity of
CIITA itself. The latter mechanism is illustrated by the ability
of human immunodeficiency virus Tat protein to interfere with
CIITA-mediated transactivation (61). Little is known regard-
ing posttranslational events that may impact on CIITA.
Prostaglandins are inflammatory mediators produced by the
action of cyclo-oxygenase in the arachidonic acid pathway.
They contribute to inflammation through vasodilation, poten-
tiating effects on permeability through histamine, bradykinin,
and leukoattractants (36). The immunomodulatory effects of
prostaglandins on macrophages have been well described.
IFN-g-induced class II MHC expression is inhibited by pros-
taglandins of the E type (PGE) in macrophages (5, 29, 59, 65).
Receptors for PGE activate adenyl cyclase leading to increased
intracellular cyclic AMP (cAMP) production and downstream
protein kinase A (PKA) activation (21). The effect of PGE on
class II MHC expression has been shown to occur at the tran-
scriptional level (2). The mechanism linking PKA to modula-
tion of IFN-g induction of class II MHC is unknown and is the
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focus of this study. Since phosphorylation is a frequent form of
posttranslational modification in eukaryotic cells and is linked
to the control of a multitude of cellular functions, we hypoth-
esized that an effect of PGE, cAMP, and PKA activation might
be the direct phosphorylation of CIITA.
In this report, we demonstrate that PGE and cAMP inhibit
the function of CIITA. Furthermore, the constitutively active
catalytic subunit (a) of PKA (PKAa) can fully reproduce the
inhibitory effects of PGE and cAMP on a class II MHC pro-
moter through phosphorylation of CIITA. Through use of the
Gal4CIITA fusion and a Gal4-driven reporter, we show that
the effects of PGE, cAMP, and PGE on promoter activation by
CIITA are independent of specific class II MHC promoter
elements. Further, we show that site-specific phosphorylation
events are important for PKA-mediated inhibition of CIITA-
dependent promoter activation.
MATERIALS AND METHODS
Cell lines and transfection. Mouse monocyte/macrophage cell lines P388D1
(ATCC TIB 63) and RAW264.7 (ATCC TIB 71) and human monocyte-like cell
line U937 (ATCC CRL 1593) were cultured in RPMI 1640 supplemented with
15% fetal calf serum, 2 mM L-glutamine, 100 U of penicillin/ml, and 100 mg of
streptomycin/ml (complete medium). For transfection, cells were harvested in
mid-log phase. Transient cotransfection was carried out by electroporation or
with the SuperFect (Qiagen) reagent. Briefly, for electroporation, 2 3 106 cells
were pelleted by centrifugation, resuspended in 300 ml of complete medium, and
transferred into a Gene Pulser cuvette (Bio-Rad Laboratories). The appropriate
plasmid DNAs were added in a total volume of 20 ml. For each treatment cells
were pulsed at 960 mF and 0.2 kV and transferred into 10 ml of complete
medium. Transfections using SuperFect were performed according to the man-
ufacturer’s directions. For cells transfected with PKA, 80 mM ZnCl2 was added
to ensure PKA kinase activity in vivo. Cells were harvested at 36 h posttransfec-
tion. The Gal4DRCAT and Gal4CIITA plasmids were a gift from Jerry Boss.
Analysis of mRNA expression. P388D1 cells (4 3 106) were transfected by
electroporation at 0.24 kV and 960 mF. Total RNA isolation was performed
using the Wizard RNA isolation kit (Promega). One microgram of total RNA
from each treatment was used for reverse transcription-PCR using class II I-Ab
primers (59-AAC CAG CCA AGA TCA AAG TGC-39 and 59-TGC CGC TCA
ACA TCT TGC TCC-39).
Phosphate labeling in vivo. For experiments involving [32P]orthophosphate or
[33P]orthophosphate labeling of CIITA proteins in vivo, 36 h posttransfection,
transfected cells (approximately 2 3 107) were washed once with phosphate-free
complete Dulbecco’s modified Eagle medium (DMEM) (15% dialyzed fetal calf
serum and supplements as for RPMI 1640 above), resuspended in 2.0 ml of
phosphate-free complete DMEM, preincubated for 30 min at 37°C in 5% CO2,
and incubated for 2 to 4 h with 2 mCi of [32P]orthophosphate or [33P]orthophos-
phate/ml. At the end of the labeling period, cells were washed once with 10 ml
of ice-cold Tris-buffered saline, lysed in 1.0 ml of radioimmunoprecipitation
assay (RIPA) buffer (1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate [SDS], 0.15 M NaCl, 0.01 M sodium phosphate [pH 7.2], 2 mM EDTA,
50 mM NaF, 0.2 mM NaVO4, 0.5 mM phenylmethylsulfonyl fluoride, 13 COM-
PLETE protease inhibitor cocktail [Roche]), and incubated for 40 min at 4oC.
Five microliters of fixed Staphylococcus aureus (Pansorbin; Calbiochem) in RIPA
buffer was added if lysates became viscous. The lysates were clarified by centrif-
ugation at 4°C for 10 min in a microcentrifuge at maximum speed (14,000 3 g),
and the supernatants were used for immunoprecipitation.
Immunoprecipitation and in vitro kinase assay. For immunoprecipitation of
FLAG-tagged CIITA, a 20-ml packed volume of monoclonal anti-Flag M2–
agarose affinity gel (A-1205; Sigma, St. Louis, Mo.) was added to cell lysates or
the in vitro-translated protein mixture and the resulting mixture was incubated at
4°C for 2 to 4 h. The beads were washed once with RIPA buffer, twice with
ice-cold phosphate-buffered saline (PBS), and once with 13 PKA buffer (10 mM
Tris [pH 7.0], 5 mM MgCl2). Pellets were incubated with PKAa at a molar ratio
of 20:1 in the presence of 10 mCi of [g-32P]ATP and 100 mM ATP in a total
volume of 10 ml of PKA buffer for 10 min at 30°C. Pellets were washed twice with
ice-cold PBS containing a mixture of protease and phosphatase inhibitors and
boiled for 5 min in 20 ml of 23 SDS sample buffer. Proteins were separated on
SDS–8% polyacrylamide gel electrophoresis (PAGE) gels, and phosphorylated
bands were visualized by autoradiography.
Enzyme activity assays. Chloramphenicol acetyltransferase (CAT) and lucif-
erase reporter assays were performed as previously described (15, 51).
Generation of CIITA mutants. Site-directed mutagenesis was performed using
the Transformer (Clontech) site-directed mutagenesis kit according to the man-
ufacturer’s instructions. Plasmid p3FGCIITA8 was used as the template in the
mutagenesis reaction. All of the primers used in this procedure were 59 phos-
phorylated. Selection primer 59-CCCTGATAAATGCTTCAATGCTAGCGAA
AAAGGAAGAGTATGAG-39 converts an existing SspI site to an NheI site,
allowing SspI restriction digest-mediated removal of the parent plasmid. Mutant
clones were confirmed by DNA sequence analysis. Site-directed mutation of
serine to alanine was achieved with the following mutagenic primers (mutated
residues are in boldface): S286A, 59-GGA GCG AAG GGG CTG GTG GCG
CCT GGC CGG TCT GGA GAT GTT GGG-39; SSS373/374/375AAA, 59-CCC
AGT CCG GGG TGG CCA GTT CCC GCT CCA GGC TCT TGG CGG CGG
CCC TCT CCA GCC TGG CCT GCA CCA GAT CCA CCT CC-39; S674A,
59-CTG GTC CTC CTG TAG GGT AGC TTG ATG TCT GCG GC-39; S834A,
59-GGC GGG TGC CCA GAA AAG CGA GGC GGC CGG GG-39; SSS942/
943/944A, 59-CCC GAA CAG CAG GGA GCT CCC CAG CTG TGT CTT
CCG CGG CAG CTC TCG TCC TCT GAG TCT GCA CAA GCT TTC CCA
GG-39.
Phosphoamino acid analysis and phosphopeptide mapping. For phos-
phoamino acid analysis, 32P-labeled CIITA was transferred to a polyvinylidene
difluoride membrane (Bio-Rad; 0.2-mm pore size). The transferred product was
visualized by autoradiography, excised from the membrane, hydrolyzed in 500 ml
of 6 N HCl by heating to 110°C for 60 min, allowed to cool, and microcentrifuged
for 2 min at maximum speed. The hydrolysate was dried under vacuum and
resuspended in 8 ml of water. Approximately 6,000 cpm of the hydrolysate was
spotted on a 20-cm2, 100-mm-thick glass-backed cellulose thin-layer chromatog-
raphy plate (EM Science). Phosphoamino acid standards (1 ml of a mixture of
phosphoserine, phosphothreonine, and phosphotyrosine; 1 mg/ml each) were
loaded as described above. The first dimension was resolved by electrophoresis
at 1,500 V for 20 min in electrophoresis buffer I (0.58 M formic acid, 1.36 M
glacial acetic acid, pH 1.9). Resolution of the second dimension was achieved
with electrophoresis at 1,300 V for 16 min in buffer II (0.87 M glacial acetic acid,
0.5% pyridine, 0.5 mM EDTA, pH 3.5). After being dried, plates were sprayed
with 0.25% (wt/vol) ninhydrin in acetone and developed at 70°C for 10 min to
visualize the phosphoamino acid standards. Autoradiography was performed to
visualize labeled CIITA fragments.
For one-dimensional phosphopeptide mapping of CIITA by cyanogen bro-
mide (CNBr), 32P-labeled CIITA was transferred to nitrocellulose (Schleicher &
Schuell) and analyzed by autoradiography. A membrane section containing the
CIITA band was excised and suspended in degassed 70% (vol/vol) formic acid.
After the suspension was flushed with nitrogen, CNBr was added to a concen-
tration of 12 mg/ml and the suspension was incubated under nitrogen at room
temperature for 4 h. The sample was diluted 10-fold with water and lyophilized.
The sample was dissolved in Laemmli sample buffer, boiled for 5 min, fraction-
ated by SDS–16% PAGE in parallel with prestained molecular weight standards,
dried, and visualized by autoradiography.
For two-dimensional phosphopeptide mapping of CIITA using trypsin, poly-
acrylamide gels (8%) containing CIITA 32P labeled in vitro by PKA were washed
three times for 10 min each in 500 ml of sterile deionized water. Following
autoradiography, the CIITA band was excised and was placed in a microcentri-
fuge tube in 200 ml of ice-cold performic acid and incubated for 60 min on ice to
achieve oxidation of the 32P-labeled CIITA. The gels were rinsed once with
water, and trypsin cleavage was performed as follows. Briefly, 0.1 mg of trypsin
(sequencing grade; Boehringer Mannheim)/ml in 1 mM HCl was diluted to 1 to
5 mg of trypsin in 100 ml with digestion buffer (50 mM ammonium bicarbonate,
pH 7.8) immediately before use, and sufficient volume to cover each gel slice was
used. After 13 h at 37°C, an additional 10-mg aliquot of trypsin was added, and
incubation continued for 8 h. Samples were then centrifuged for 30 min, and the
supernatants were diluted with 400 ml of water and then lyophilized under
vacuum. The tryptic digests were resuspended in 400 ml (pH 1.9) of electro-
phoresis buffer and lyophilized again. The digests were then dissolved in 5 to 10
ml of electrophoresis buffer, pH 1.9 (15% acetic acid, 5% formic acid). Phos-
phopeptides were separated in the first dimension by electrophoresis in the same
buffer on a thin-layer chromatography cellulose plate (EM Laboratories) at 1,000
V for 65 min using an HTLE 7000 apparatus (C.B.S. Scientific). Plates were then
dried and subjected to ascending chromatography in the second dimension for
12 h with 37.5% butanol–25% pyridine–7.5% acetic acid. Radiolabeled phos-
phopeptides were detected by phosphorimaging.
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RESULTS
PGE1, PGE2, 8-bromo-cAMP, and PKA inhibit activation by
CIITA. Previous reports have demonstrated the inhibition of
constitutive and inducible class II MHC transcription and pro-
tein expression by PGE1 and PGE2 (2, 20, 30, 59). As both
constitutive and inducible class II MHC transcription is con-
tingent on CIITA, we hypothesized that this inhibition might
involve posttranslational modification of CIITA. To investigate
the effect of prostaglandin treatment on the ability of CIITA to
activate transcription, we coexpressed CIITA fused to the Gal4
DNA-binding domain (Gal4CIITA) and a luciferase reporter
containing five upstream Gal4 binding sites (Gal5Luc) in
P388D1 cells and treated the cells with 0.25 to 1.0 mM PGE1 or
PGE2. The P388D1 cells were chosen because they were used
extensively in previous studies analyzing the effects of PGE on
class II MHC expression. Use of the Gal5 reporter system is
crucial because it allowed us to focus on CIITA-specific effects
independent of class II MHC-associated transcription factors.
The effect of PGE1 or PGE2 treatment on Gal5Luc reporter
activation is shown in Fig. 1. Both PGE1 and PGE2 inhibited
the ability of Gal4CIITA to activate transcription in a dose-
dependent fashion (Fig. 1A and B). At the highest concentra-
tions of PGE, inhibition is approximately fivefold. The maxi-
mal concentrations of PGE had no suppressive effect on
activation of the Gal5Luc reporter by an unrelated Gal4–
DNA-binding domain fusion containing an N-terminal dele-
tion of the p65 subunit of NF-kB (Gal4p65DN) (Fig. 1C).
Prostaglandins also inhibit, to a similar extent, class II MHC
transcription and promoter function (Fig. 1D and E), consis-
tent with data using the Gal5Luc system. This demonstrates
that the ability of CIITA to activate transcription can be sup-
pressed by PGE1- or PGE2-mediated events.
The effects of PGE are mediated largely through the acti-
vation of adenyl cyclase and subsequent production of second
messenger cAMP, which then activates cAMP-dependent PKA
(55). Given our observations that PGE1 and PGE2 can sup-
press transcriptional activation by CIITA, we reasoned that
cAMP treatment should have a similar effect. To this end, we
analyzed the effect of 8-bromo-cAMP treatment in our system.
As anticipated, cAMP treatment of Gal4CIITA-expressing
cells also shows suppression of Gal5Luc activation (Fig. 2A).
8-Bromo-cAMP treatment had a similar effect on CIITA-me-
diated transcription from the DR promoter (Fig. 2B).
To determine if activation of PKA regulates CIITA activity,
we examined the effects of transfected PKA on CIITA activity
in vivo using transiently transfected cells. As expected, cells
transfected with a Gal4-binding site CAT reporter construct
(Gal4DRCAT) (53) alone show only a basal level of CAT acet-
ylation while cotransfection of Gal4DRCAT and Gal4CIITA
results in increased reporter activity (Fig. 3A). Significantly,
cotransfected constructs encoding the catalytic subunit of
PKAa, but not PKAb, completely suppress DR promoter ac-
tivity induced by CIITA. This is observed with either
Gal4CIITA or the unmodified CIITA construct. To assess if
similar treatments might alter class II MHC gene expression in
response to IFN-g, we examined the effect of transfected
PKAa on IFN-g-induced class II MHC promoter activation.
As shown in Fig. 3B, transfection of PKAa inhibited promoter
activation following treatment with mouse IFN-g. To further
determine if these effects could be extended to the endogenous
FIG. 1. PGE1 and PGE2 inhibit CIITA-mediated transactivation. P388D1 cells were transfected with the plasmid DNAs shown and treated
with the indicated concentrations of either PGE1 (A, C, and D) or PGE2 (B, C, and E). Luciferase or CAT activity was determined as described
in Materials and Methods. Transcriptional activity is expressed as a percentage relative to activity using untreated, wild-type Gal4CIITA (A, B,
and C) or CIITA (D and E). Results are presented as the means 6 standard deviations of three separate experiments.
4628 LI ET AL. MOL. CELL. BIOL.
class II MHC genes, the effects of these treatments on the
CIITA-induced expression of class II MHC transcripts were
measured. Levels of expression of the induced, endogenous,
class II MHC message following either IFN-g treatment or
transfection of CIITA were comparable (Fig. 3C, lanes 1 to 3).
Consistent with the reporter assays, PGE1, cAMP, and cotrans-
fected PKAa all had similar effects on expression of class II
MHC mRNA in cells transfected with CIITA (Fig. 3C, lanes 4
to 6). PKAa-mediated inhibition of CIITA-induced transcrip-
tion was also observed in a monocytic cell line of human
(U937) and mouse (RAW264) origins (Fig. 3D), indicating
that this effect is not specific for the P388D1 cell line. These
results demonstrate that PKA can inhibit the ability of CIITA
to activate transcription.
Taken together, the observations that PGE, cAMP, and
PKA all inhibit the transactivation function of CIITA suggest
that the PGE-, cAMP-, or PKA-mediated inhibition of class II
MHC transcription and expression is achieved through modu-
lation of CIITA activity. Furthermore, as the class II MHC
transcription factors (i.e., RFX and NF-Y) are not required for
activity using the Gal5Luc reporter, this mode of inhibition
may be specific for CIITA and independent of class II MHC
promoter-specific transcription factors.
Phosphorylation of the CIITA protein by PKA and phos-
phoamino acid analysis. As the above experiments implicated
the PKA pathway in the modulation of CIITA activity, we
examined the phosphorylation state of CIITA in vitro and in
vivo (Fig. 4). For in vitro phosphorylation, the Flag-tagged
CIITA protein was either expressed in transfected P388D1
cells or in vitro translated. The resulting proteins were immu-
noprecipitated and incubated with the catalytic subunit of
PKAa in the presence of [g-32P]ATP. CIITA immunoprecipi-
tated from transfected-cell lysate is readily phosphorylated by
PKAa (Fig. 4a, lane 1). In vitro-translated CIITA is also sub-
ject to phosphorylation by PKAa (lane 2). Phosphorylation
was observed in the presence of PKAa (lanes 1 and 2) but not
in the presence of a selection of other kinases, including cyclic
GMP-dependent protein kinase, protein kinase C, calmodulin-
dependent protein kinase II, and growth-associated histone H1
kinase (MPF, cdc21/CDC28 protein kinase) (lanes 5 to 8).
These data demonstrate that CIITA is a substrate for PKA in
vitro. Next, we determined whether CIITA could be phosphor-
ylated in vivo. CIITA expressed in transfected P388D1 cells
and cultured in the presence of 32Pi reveals a modest level of
phosphorylation (Fig. 4, lane 9), which increases markedly
when the cells are cotransfected with both CIITA and PKAca
(lane 10). The relatively low level of basal CIITA phosphory-
lation may indicate the relative inactivity of PKA in P388D1
cells. Alternatively, the observed phosphorylation may also be
due to other serine-specific protein kinases (see below). Sev-
eral lighter bands were also phosphorylated and may represent
nonspecific proteins bound by protein A- or G-agarose. How-
ever, the observed increase in 32P incorporation in the pres-
ence of PKAa demonstrates that CIITA can be phosphory-
lated in vivo by PKA.
Phosphoamino acid analyses were performed using either in
vitro- or in vivo-expressed CIITA phosphorylated by PKA (Fig.
4). In both cases, we observed that phosphorylation occurred
exclusively on serine residues. No phosphothreonine or phos-
photyrosine was detected in the in vitro sample, even when the
thin-layer chromatography plate was exposed to film for up to
2 weeks. This pattern of phosphorylation was identical to that
seen with in vivo-expressed CIITA (Fig. 4C). Thus, these data
provide strong evidence that any putative PKA phosphoryla-
tion sites in CIITA will contain only serine residues as the
potential phosphate receptor.
Identification of PKA phosphorylation sites in CIITA. Ten
potential PKA phosphorylation site motifs containing serine
residues (RXS and RXXS) were identified in CIITA (Ser286;
Ser375 and -376; Ser674; Ser834; Ser942, -943, and -944;
Ser1050; and Ser1128). To determine which of these residues
were likely phosphorylated, the CIITA protein was phosphor-
ylated in vitro with PKA and subjected to CNBr digestion (Fig.
5). Five predicted CNBr fragments encompassed the putative
PKA phosphorylation sites. Phosphorylated bands of the pre-
dicted molecular weights were observed for each of the five
predicted CNBr fragments, suggesting that all 10 putative PKA
sites were potentially phosphorylated.
To further analyze CIITA phosphorylation by PKA, we pre-
pared six CIITA mutant constructs in which various groupings
of these 10 serine residues were mutated to alanine (Fig. 6A).
These included three single mutants, two with five different
mutated serine residues, and one with four serine residues
mutated. Each of these mutants was translated normally in
vitro and in cells, and PKA was able to phosphorylate all of the
mutants to various degrees (Fig. 6B); however, mutants with
FIG. 2. cAMP inhibits CIITA-mediated transactivation. Transcrip-
tional activation by Gal4CIITA (A) or CIITA (B) was determined
using P388D1 cells transfected with the indicated plasmid DNAs and
cultured in the absence or presence of increasing concentrations of
8-bromo-cAMP as indicated. Relative activation (as a percentage) is
shown as described for Fig. 1. Values are means 6 standard deviations
from three separate experiments.
VOL. 21, 2001 PHOSPHORYLATION OF CIITA BY PKA 4629
four (M10-8) or five serine mutations (M10-2 and M9-33)
showed as much as a 50% decrease in PKA phosphorylation.
These observations are consistent with phosphorylation occur-
ring at most if not all the putative PKA sites.
A further delineation of the phosphorylated serine residues
was accomplished by two-dimensional tryptic phosphopeptide
mapping of wild-type and mutant CIITA proteins translated in
vitro (Fig. 6C). A comparison of two-dimensional tryptic phos-
phopeptide maps from wild-type CIITA and mutant forms of
CIITA allowed the assignment of specific serine residues by
their absence on autoradiograms. We were able to resolve 10
phosphopeptide spots corresponding to locations that were
clearly associated with the PKA consensus phosphorylation
site motifs in CIITA. Three of these spots correspond to oxi-
dized phosphopeptides (S286 and S674) or partial digestion
products (S674). Two spots correspond to phosphopeptide
fragments with multiple putative phosphorylation sites (S942,
-943, and -944 and S375 and -376). These findings demonstrate
that in vitro CIITA contains phosphorylated serines at the
predicted PKA sites. Given the increased spot intensities seen
for the two sites with multiple serines, S375 and -376 and S942,
-943, and -944, and the decreased phosphorylation of the S375
and -376 spot when S375 is mutated (M9-33), it is probable
that S375, S376, and at least two of the three serines from 942
to 944 are phosphorylated.
Mutation of PKA sites in CIITA abolish PKA-mediated in-
hibition of CIITA. We have attempted in vivo phosphopeptide
analysis of CIITA mutants in the presence of PKA; however
these analyses were extremely difficult due to the low level of
CIITA in P388D1 cells and the formidable amount of radio-
isotope required. As an alternative, experiments were per-
formed to test the ability of PKAa to inhibit the transactivation
of the HLA-DR promoter by wild-type CIITA or CIITA PKA
site mutants in P388D1 cells. Wild-type CIITA or the PKA site
mutants were cotransfected together with either a control plas-
mid or the PKAa plasmid, and activation of the DR promoter-
driven CAT reporter was examined (Fig. 7). Without cotrans-
fected PKA, all of the CIITA PKA site mutants retained some
ability to activate transcription (approximately 40 to 130% of
that of wild-type CIITA). A modest to significant reduction of
transactivation in the absence of PKA occurs when PKA sites
in the C-terminal portion of CIITA are mutated (S834, S942 to
-944, and S1050; mutants S834A, S1050A, M10-2, and M9-33).
Mutation of S1128 did not decrease the function of CIITA.
FIG. 3. PKAa inhibits CIITA-mediated transactivation. (A) PKAa inhibits CIITA-mediated promoter activation. Gal4DRCAT and
Gal4CIITA (bars 1 to 4) or ddDrCAT and p3FgCIITA (bars 5 and 6) together with plasmids encoding either the PKAa or PKAb catalytic subunit
(c) were cotransfected into P388D1 cells. (B) PKAa represses IFN-g-induced promoter activity. P388D1 cells were transfected with 300DRLuc
with or without cotransfection of PKAa and cultured in the presence or absence of recombinant mouse IFN-g (rIFN-g). (C) PKAa inhibits
CIITA-mediated transcription of endogenous class II MHC. P388D1 cells were transfected with empty vector or wild-type CIITA and treated as
indicated. Cells were treated with IFN-g (0.8 ng/ml), PGE1 (1.0 mM), or cAMP (1.0 mM) or cotransfected with PKAa as indicated. Expression of
mRNA was determined by reverse transcription-PCR (see Materials and Methods). (D) PKAa inhibits CIITA-mediated transactivation in
monocytic cell lines. The monocytic cell lines U937 and RAW264 were cotransfected with 300DRLuc and CIITA with or without PKAa using
SuperFect (Qiagen). CAT (A) and luciferase (B and D) activities were determined at 36 h posttransfection. The data are the means 6 standard
deviations of three experiments and are shown normalized to the activity of Gal4CIITA or CIITA on the Gal4DRCAT or 300DRLuc reporter,
respectively (100%).
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Mutation of the more-N-terminal PKA sites S286 and S375
and -376 (M10-8) led to a modest increase in transactivation
compared to that for wild-type CIITA (130%). Coexpression of
PKAa reduces transcriptional activation by wild-type CIITA to
20% of that seen without PKAa (Fig. 7). Mutants S834A and
S1050A are not inhibited by PKAa coexpression at all, indi-
cating that serine residues 834 and 1050 are crucial for PKAa-
mediated suppression of CIITA function. In fact, a small but
reproducible degree of enhanced transcriptional activation is
observed with these two mutants.
In contrast, S1128A and M10-8, mutants that display no
decrease in transactivation in the absence of coexpressed PKA,
are significantly inhibited in the presence of PKA. The inhibi-
tion of these mutants in the presence of PKA is less that of the
wild-type CIITA, suggesting that the mutated serines (S286,
S374, -375, and -376, and S1128) may play a role in PKA-
mediated inhibition of CIITA function but that they are not
the key residues involved in this inhibition.
M10-2 and M9-33 display a profile similar to that for S834A
and S1050A in that they are no longer susceptible to PKAa-
mediated suppression. The latter two constructs contain the
S834A and S1050A mutations, consistent with the conclusion
that residues 834 and 1050 are crucial. In addition to mutations
at S834 and S1050, M10-2 is also mutated at S942 to -944, but
the role of these residues is unresolved. Similarly, M9-33 is
mutated at S943 and S1128 in addition to S834 and S1050. The
characterization of the S1128A mutant described above ruled
out a role for this residue in PKA-mediated suppression of
CIITA activity. The role of S943 alone is presently unclear.
Nonetheless, these data are compatible with the conclusion
that the phosphorylation at S834 and S1050 correlates directly
with the ability of PKA to inhibit the transactivation of
HLA-DR by CIITA. This indicates that the observed action of
PKA agonists (PGE, cAMP, forskolin, etc.) on class II MHC
genes is likely mediated through phosphorylation of these two
residues, although additional serine residues may play a minor
role.
DISCUSSION
It has been appreciated for some time that PGE treatment,
which increases intracellular cAMP, leads to downregulation
of class II MHC surface expression in a transcription-depen-
dent fashion (21, 29, 59). The mechanism by which PGE and
cAMP modulate transcription has not been addressed previ-
ously. Because the likely targets for such regulation are the
transcription factors which regulate class II MHC expression,
we examined the class II transactivator (CIITA) as a potential
target for PGE- and cAMP-mediated transcriptional repres-
sion of class II MHC genes. Here we present compelling evi-
dence that PGE-mediated repression of class II MHC tran-
scription involves the phosphorylation of CIITA by PKA.
PGE1, PGE2, 8-bromo-cAMP, and PKA all repress class II
MHC transcription and also reduce Gal4CIITA-mediated
transcription of a Gal4 binding site containing a promoter
FIG. 4. CIITA phosphorylation assay in vitro and in vivo with PKA.
(a) Lane 1, CIITA immunopurified from transfected-cell lysate; lanes
2 to 4, in vitro-translated and immunopurified CIITA was tested for
phosphorylation by PKA with negative controls; lanes 5 through 8,
immunopurified CIITA from translation in vitro was assayed for phos-
phorylation capability with kinases of cGMP-dependent protein ki-
nase, protein kinase C, calmodulin-dependent protein kinase II, and
growth-associated histone H1 kinase; lane 9, immunopurified CIITA
from transiently transfected cells labeled with [32P]orthophosphate in
vivo; lane 10, immunopurified CIITA labeled with [33P]orthophos-
phate in vivo from P388D1 cells transiently cotransfected with CIITA
and PKAa. (b) Two-dimensional phosphoamino acid analysis using
[g-32P]ATP-labeled CIITA in vitro obtained from lane 2. (c) Two-
dimensional phosphoamino acid analysis using [33P]orthophosphate-
labeled CIITA in vivo obtained from lane 10.
FIG. 5. Mapping of PKA phosphorylation sites in CIITA. (A) Di-
agram of CIITA showing potential PKA phosphorylation sites, relative
positions of CNBr cleavage sites, and the predicted molecular masses
of each cleavage product. Potential PKA phosphorylated serine resi-
dues are in boldface. (B) One-dimensional phosphopeptide mapping.
Digestion of phosphorylated CIITA was performed with CNBr to
generate peptides. Arrows, expected CNBr cleavage peptide frag-
ments; the corresponding predicted molecular masses are shown. Pep-
tides were separated by SDS-PAGE (16%). The observed molecular
weights of 32P-labeled fragments are based on migration of molecular
weight standards.
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lacking W-, X-, and Y-box elements. This suggests that the
effects of PGE on class II MHC transcription may be largely
independent of the factors that bind these elements. While
PKAa is sufficient for these effects, PKAb is not, indicating the
specific activation of PKAa in PGE-mediated modulation of
class II MHC expression. In support of these observations
PKA can phosphorylate CIITA both in vitro and in vivo, sug-
gesting that direct phosphorylation of CIITA is critical. Four
other serine/threonine kinases failed to phosphorylate CIITA
in vitro, demonstrating that phosphorylation of CIITA is likely
kinase specific. Furthermore, functional characterization and
phosphopeptide mapping of PKA site mutations reveal that,
despite numerous PKA phosphorylation sites within CIITA,
only two individual phosphorylation sites can be unambigu-
FIG. 6. CIITA mutants and identification of PKA phosphorylation sites in CIITA. (A) Diagram of CIITA serine mutants. All mutants were
sequenced to confirm the absence of deleterious mutations. (B) In vitro translation in the presence of [35S]Met revealed that every mutant yielded
a full-length product (top). Bottom, in vitro phosphorylation using [32P]ATP. (C) Two-dimensional phosphopeptide mapping. Wild-type and
mutant CIITAs were synthesized in vitro, immunoprecipitated with mouse monoclonal anti-Flag, and phosphorylated with PKA. Labeled proteins
were separated by SDS-PAGE and excised for in-gel digestion with trypsin. Phosphopeptides generated by tryptic cleavage were separated by
electrophoresis (horizontal dimension; pH 1.9; cathode on right) and thin-layer chromatography (vertical dimension) and detected by autora-
diography.
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ously linked to the repressive effects of PKA. Taken together
these results demonstrate a PKA-mediated regulation of
CIITA transactivation function and describe a mechanism by
which PGEs can modulate transcription of class II MHC
genes.
Mechanistic studies prior to this report suggested that ele-
ments within the class II MHC promoter were required for the
inhibitory effects of cAMP and PKA on class II MHC tran-
scription in B cells (30). S- and X-box sequences appeared to
be somewhat important for repression, but the low degree of
reporter activity using either mutations in individual promoter
elements or deletions made it difficult to interpret the observed
loss of repression. With this caveat in mind, mutation of the X2
box, which contains a consensus cAMP response element
(CRE), had no effect on PKA-mediated repression but had a
substantial effect on constitutive reporter activity. The CRE
binding protein (CREB) is activated by PKA and activates
many cAMP response promoters through phosphorylation-de-
pendent recruitment of coactivator CBP (16, 32, 35, 47).
CREB has been identified as a protein that can bind X2 (43)
and interacts with CIITA as part of the class II MHC tran-
scriptional scaffold (64). In murine macrophage cell line
P388D1, transcriptional repression of IFN-g-induced class II
MHC by PKA was not affected by mutations in the S, X1, X2,
or Y boxes or by complete deletion of S, X1, and X2 (29).
However, as in the B-cell study, these mutations did diminish
IFN-g-induced promoter activity from 40 to 70%.
Our identification of CIITA as a target in the PGE/cAMP/
PKA pathway is not inconsistent with these previous studies.
IFN-g induces the expression of CIITA, and CIITA is gener-
ally required for class II MHC transcription and expression
(reviewed in reference 27). Thus CIITA is a critical component
of the IFN-g signaling pathway necessary for class II MHC
transcription. At the level of the class II MHC promoter, the
W, X, and Y elements are essential for full transcriptional
activation. Deletion or mutation of individual sequence ele-
ments from class II MHC promoters substantially reduces the
induction seen with IFN-g or CIITA (29, 54, 64). As CIITA-
dependent transcription is practically abolished by the intro-
duction of PKA and individual phosphorylation site point mu-
tations in CIITA completely block the effect of PKA, it is
highly probable that CIITA is a principal target of the PGE
pathway with regard to class II MHC expression in these cells.
This hypothesis is supported by our observation that the PGE/
cAMP/PKA pathway also inhibits Gal4CIITA activity on a
promoter without class II MHC-specific promoter elements.
Repression of CIITA activity by PGE is in the range of 2.5- to
5-fold (Fig. 1). In experiments using cAMP, the degree of
suppression is similar (Fig. 2). The effects of PGE and cAMP
addition may differ, as the effects of added cAMP may be
muted due to the cAMP-depleting activity of phosphodiester-
ases and the lack of a sustained signal (such as PGE) to main-
tain cAMP generation. PGE, cAMP, and PKA treatment also
inhibited transcription of endogenous class II MHC, and the
extents of repression by these treatments are comparable. An
important caveat in using the Gal4CIITA system is that the
contributions of X- and Y-box transcription factors are circum-
vented by employment of the Gal4 DNA-binding domain such
that CIITA is directed to the promoter without RF-X, NF-Y,
CREB, etc. However, with this system, modifications that di-
rectly impact the ability of CIITA to activate transcription can
be observed. Although there is congruence in both our re-
porter systems (Fig. 1 and 2), we have not ruled out the pos-
sibility that disrupted interactions with the essential X- and
Y-box binding proteins are another consequence of PKA-me-
diated CIITA phosphorylation. In addition, PKA phosphory-
lation of CREB may have other effects on the class II MHC
promoter independent of CIITA phosphorylation events. It is
also reasonable to consider the possibility that S834 and S1050
of CIITA may be potential targets for other serine kinases with
potential roles in regulating class II MHC expression.
By what mechanism does phosphorylation regulate CIITA?
This is a key question arising from the results of this study. A
priori, the regulatory effects of CIITA phosphorylation could
be either positive or negative. Phosphorylation of CIITA could
permit binding to the requisite transcription factors, thus pos-
itively modulating transactivation. Phosphorylation events
leading to protein dimerization followed by productive DNA
binding on a promoter are common (e.g., CREB [16] and
STATs [14, 17, 18]). This mechanism seems plausible, as the
mutation of certain phosphorylation sites in CIITA can down-
regulate its ability to activate transcription. However, our data
FIG. 7. Suppression of CIITA and phosphorylation mutants by
PKAa. (A) P388D1 cells were transiently cotransfected with 5 mg of
the indicated plasmids and 2 mg of the DRCAT reporter. CAT activity
was assayed and expressed relative to that for wild-type CIITA in the
absence of exogenous PKA. The averages of three independent exper-
iments 6 standard deviations are shown. (B) Diagram of the observed
effect of PGE-signaling events on class II transcription.
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indicate that phosphorylation of CIITA by PKA leads to a loss
of transactivation ability. This effect is associated with phos-
phorylation at residues 874 and 1050 of CIITA. Based on our
current understanding of CIITA function, there are a number
of possibilities that could allow for the observed negative reg-
ulation. The simplest is that phosphorylation of S874 and
S1050 leads to failed nuclear localization. Nuclear import of
yeast transcription factor Pho4 is regulated by a number of
serine phosphorylation events (33). Thus far, attempts to visu-
alize CIITA localization by immunofluorescence in the
P388D1 cell line have been unsuccessful due to the extremely
low levels of CIITA expression (data not shown). In Cos-7
cells, all of the mutants examined in this study had substantial
cytoplasmic staining, although nuclear CIITA was detectable
in all but M10-8 and M9-33 (data not shown). However, the
effects of PKA are apparent even when using a Gal4CIITA
fusion that contains Gal4 nuclear localization sequences,
strongly suggesting that the effect of PKA is not an alteration
of nuclear localization. Another possibility is that phosphory-
lation of CIITA disrupts a critical protein-protein interaction.
Transcription factors RFX5, RFX-ANK, NF-YB, NF-YC, and
CREB have been shown to bind CIITA (19, 41, 56, 64), as have
several components of the basal transcription machinery, in-
cluding CBP (23, 34), TFIID (40), and various TATA-binding
protein-associated factors (22, 40). Treatment of in vitro-trans-
lated CIITA with PKA did not disrupt the binding of CIITA to
glutathione S-transferase-CBP fusion proteins in a pull-down
assay (data not shown), although this was not surprising as the
important serine residues are quite distant from CIITA’s N-
terminal CBP binding site (23, 34). None of the CIITA-inter-
acting transcription factors mentioned above mapped to a re-
gion near amino acid 874 or 1050 of CIITA (64). This suggests
that, while disrupting these interactions via phosphorylation is
plausible, it would require a mechanism more complex than
simple inhibition of a binding site. Our data support this idea
to some extent. PKA is able to inhibit transactivation of the
Gal5 promoter by Gal4CIITA and transactivation from DR by
wild-type CIITA. We conclude that this reflects an indepen-
dence from the specific promoter elements. The observation
also suggests that the effect of phosphorylation is likely to
affect the activation domain of CIITA despite its distance from
the phosphorylation site. A reasonable hypothesis is that a
conformational change alters the accessibility of the activation
domain and permits or disallows contact with an important
protein. Phosphorylation might affect the folding or conforma-
tion of CIITA. Recently, our laboratory has observed that the
leucine-rich repeats and sequences in or near the GTP-binding
site of CIITA mediate homotypic and heterotypic self-associ-
ation of CIITA (37). Although the exact role that these asso-
ciations play is presently unclear, it is conceivable that phos-
phorylation at S874 and S1050 might influence some presently
unknown mechanistic step involving one of more of these self-
associations. Another possibility is that phosphorylation tar-
gets CIITA for degradation. This has been observed for IkB,
the regulator of rel-family transcription factor NF-kB (4), and
with c-myb, a transcription factor involved in hematopoiesis
(6).
In summary, this work explains the long-observed finding
that prostaglandins and cAMP treatment of macrophages
cause the inhibition of IFN-g-induced class II MHC gene ex-
pression. This is the first documentation that PGE, cAMP, and
PKA can all inhibit CIITA function. This inhibition occurs
through the phosphorylation of CIITA, and at least two critical
serine residues, S874 and/or S1050, have been identified as the
crucial kinase targets. Elucidation of the precise mechanisms
involved should prove informative and increase our under-
standing of CIITA function in macrophage and nonmacroph-
age cells.
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